



Neurotech confirms new appointments including Independent Non-Executive Chairman

Malta & Perth, Australia – 16 April 2019 – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) is pleased to announce several new appointments, effective immediately, including:

- Mr Mark Davies as Independent Non-Executive Chairman
- Mr Winton Willesee as Independent Non-Executive Director
- Ms Eryln Dale as Company Secretary

The new appointments have been made in line with the Company’s revised commercial strategy to ensure the best path toward maximising shareholder value. The relevant skills and qualifications of each of the new appointments is outlined below in Annexure A.

Concurrently with the new appointments, Mr Peter O’Connor, Mr Simon Trevisan and Dr Neale Fong have retired as directors of the company, while Ms Fleur Hudson has retired as Company Secretary. The Company would like to thank the outgoing directors for their hard work and support. Mr O’Connor and Mr Trevisan joined as directors prior to the Company’s IPO in 2016 and have worked tirelessly since. Mr Fong joined the board in 2018 and has provided a specialist health sector perspective which has been greatly appreciated.

Incoming Chairman Mark Davies said: “Neurotech has faced several recent challenges but remains in a unique position with a scientifically proven product, ready to sell into a large market. I am pleased to take on the challenge at an important time for the company and ensure we target the best possible outcomes for shareholders.”

Neurotech CEO Peter Griffiths said: “I’d like to thank the outgoing board members and the corporate services team for their long-term partnership, advice and support. Our Mente Brain Training Therapy is helping children with Autism relax, focus and engage with those around them. I look forward to working with Mark, our board, our dedicated employees and our key partners to grow the business and improve the lives of children and families coping with Autism.”

Annexure A

Mark Davies – BCom

Mark Davies graduated from the University of Western Australia with a Bachelor of Commerce. He has over 20 years’ experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital.

Mark specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 225 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

Winton Willesee – BBus, DipEd, PGDipBus, MCom, FFin, CPA, GAICD, FGIS/FCIS

Mr Willesee is an experienced company director and company secretary. Mr Willesee has considerable experience with ASX listed and other companies over a broad range of industries having been involved with many successful ventures from early stage through to large capital development projects.

Mr Willesee holds a Master of Commerce, a Post-Graduate Diploma in Business (Economics and Finance), a Graduate Diploma in Applied Finance and Investment, a Graduate Diploma in Applied Corporate Governance, a Graduate Diploma in Education and a Bachelor of Business. He is a Fellow of the Financial Services Institute of Australasia, a Graduate of the Australian Institute of Company Directors, a Member of CPA Australia and a Fellow of the Governance Institute of Australia and the Institute of Chartered Secretaries and Administrators/Chartered Secretary.

Erlyn Dale – BCom., GradDipACG, AGIA, ACIS

Ms Dale is an experienced company secretary, having held positions as company secretary for a number of ASX listed public companies across a diverse range of industries including resources, technology, industrials and health care.

Ms Dale has completed a Bachelor of Commerce (Accounting and Finance) and a Graduate Diploma of Applied Corporate Governance and is an Associate Member of both the Institute of Chartered Secretaries and Administrators and the Governance Institute of Australia.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device *Mente* and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech and *Mente* Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420